| Literature DB >> 24453973 |
Kim Dohlich1, Anna Brotcke Zumsteg2, Christian Goosmann3, Michael Kolbe1.
Abstract
The Type III Secretion System (T3SS) is a macromolecular complex used by Gram-negative bacteria to secrete effector proteins from the cytoplasm across the bacterial envelope in a single step. For many pathogens, the T3SS is an essential virulence factor that enables the bacteria to interact with and manipulate their respective host. A characteristic structural feature of the T3SS is the needle complex (NC). The NC resembles a syringe with a basal body spanning both bacterial membranes and a long needle-like structure that protrudes from the bacterium. Based on the paradigm of a syringe-like mechanism, it is generally assumed that effectors and translocators are unfolded and secreted from the bacterial cytoplasm through the basal body and needle channel. Despite extensive research on T3SS, this hypothesis lacks experimental evidence and the mechanism of secretion is not fully understood. In order to elucidate details of the T3SS secretion mechanism, we generated fusion proteins consisting of a T3SS substrate and a bulky protein containing a knotted motif. Because the knot cannot be unfolded, these fusions are accepted as T3SS substrates but remain inside the NC channel and obstruct the T3SS. To our knowledge, this is the first time substrate fusions have been visualized together with isolated NCs and we demonstrate that substrate proteins are secreted directly through the channel with their N-terminus first. The channel physically encloses the fusion protein and shields it from a protease and chemical modifications. Our results corroborate an elementary understanding of how the T3SS works and provide a powerful tool for in situ-structural investigations in the future. This approach might also be applicable to other protein secretion systems that require unfolding of their substrates prior to secretion.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24453973 PMCID: PMC3894212 DOI: 10.1371/journal.ppat.1003881
Source DB: PubMed Journal: PLoS Pathog ISSN: 1553-7366 Impact factor: 6.823
Figure 1IpaB-Knot fusions and functional analysis.
(A) Schematic of the fusion protein consisting of virulence factor IpaB and the knot-forming domain Knot with a C-terminal Strep-tag. Second construct with an embedded TEV-protease cleavage site inbetween IpaB and the Knot. Third construct of Knot separated from IpaB. (B) Murine bone marrow macrophages were treated with different concentrations of IpaB-Knot. LDH release was measured by absorption in a colorimetric assay as a marker for cellular disintegration. Error bars indicate SEM, n = 3 independent experiments. (C) Tryptophan fluorescence of IpaB-Knot compared to Knot under native (solid lines) and denaturing (dashed lines) conditions in the presence of 6 M Guanidine HCl. Fluorescence intensity was normalized to 1.
Figure 2Invasion is attenuated in M90T carrying the fusion allele.
(A) Invasion assay with wildtype S. flexneri M90T, the non-invasive ΔipaB and M90T with the fusion allele(M90T::ipaBknot, quantified by colony forming-units (CFU) per ml of culture. Error bars indicate standard deviation, performed as duplicates (bacterial clones), n = 3 technical replicates, analysis by multiple t-tests. (B) Western blot analysis of IpaB (anti-IpaB mouse monoclonal), MxiG as a marker for NCs (anti-MxiG mouse monoclonal), DnaK as a loading control (anti-DnaK mouse monoclonal).
Figure 3Substrate-Knot effects on secretion in ΔipaD.
(A) SDS PAGE/Coomassie staining of precipitated supernatants from overnight-grown TSB cultures. Samples were analyzed in duplicate and normalized to OD 2/ml. (B) Western Blot analysis of SepA (T3SS-independent protein), IpaC, IpaB and DnaK (intracellular chaperone/lysis control) in supernatants (left) and whole-cell lysates (right). (C) SDS PAGE/Coomassie staining of precipitated culture supernatants from controls, ipaB- and effector-fusion strains. Samples normalized to OD 2/ml. (D) Western Blot analysis from samples from (C) detecting Strep-tag (fusion protein expression marker), IpaC, and DnaK (intracellular chaperone/lysis control) in supernatants (left) and whole-cell lysates (right).
Figure 4Co-localization of IpaB, IpaB-Knot and isolated NC.
CsCl fractionation of NC from ipaD (left panel) and ipaD::ipaBknot (middle panel) or recombinant IpaB-Knot (rIpaB-Knot) (right panel). Samples were analyzed by Western blot with IpaB and MxiG antibodies.
Figure 5Immuno-electron microscopy of NCs and IpaB-Knot.
Micrographs of NCs labeled with anti-IpaB antibody and gold-conjugated (12 nm) secondary antibody with IpaB localized at the NC tip (A). Strep-tag labeling with anti-Strep-antibody at the NC base (B). (C) Nearest-neighbor analysis of gold particles and isolated NCs. Relative counts of distances from 50 images are plotted (dark-green), together with random distributions of NCs and gold (light green) for each image. (D) Double-labeling with anti-IpaB antibody and gold-conjugated (6 nm) anti-human secondary antibody and anti-Strep antibody with 12 nm gold-conjugated anti-mouse secondary antibody. IpaB epitope localizes at the tip, Strep epitope at the basal side of the NC.
Figure 6Protection and proteolysis of IpaB-TEV-Knot with isolated NCs and purified IpaB-TEV-Knot.
(A) Sample supernatants and bead fractions from NC isolates from ipaD::ipaBTEVknot (upper panel) and purified IpaB-TEV-Knot (lower panel) were analyzed by Western blot with IpaB and MxiG antibodies after treatment with TEV protease. (B) Purified IpaB-TEV-Knot (left panel, rIpaB-TEV-Knot) or IpaB-TEV-Knot from NC isolates untreated (−) or treated with 0.5 mM MS(PEG)24 (+) analyzed by Western blot with Strep-tag antibody.
Bacterial strains and plasmids used in this study.
| bacterial strain | source |
|
| serovar 5a isolate |
|
| Lab collection |
|
| this study |
|
| this study |
|
| this study |
|
| this study |
|
| this study |
|
| Novagen |
| plasmid backbone | insert |
| pASK-IBA3+ |
|
| pASK-IBA3+ |
|
| pASK-IBA33+ |
|
| pET28a |
|
Bacterial strains and expression plasmids used.
Oligonucleotides for genetic modifications performed.
| purpose | sequence (5′ to 3′) |
|
| |
| 5′ chloramphenicol forward, flanking |
|
| 3′ chloramphenicol reverse, flanking |
|
|
| |
| 5′ |
|
| 5′ |
|
| 5′ |
|
| 5′ |
|
| 5′ |
|
| 3′ |
|
| 5′ chloramphenicol forward, overlapping oligonucleotide for |
|
| 3′ chloramphenicol reverse for |
|
| 3′ chloramphenicol reverse for |
|
| 3′ chloramphenicol reverse for |
|
Oligonucleotides used for either genetic fusions or gene deletions.